Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05186818 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM
A Phase 3 study of Obstructive Hypertrophic Cardiomyopathy (oHCM), sponsored by Cytokinetics.
- Completed
- Registry status
- Phase 3
- Development phase
- 282
- Enrollment target
- 20
- Study locations
NCT05186818: Completed Phase 3 study of Obstructive Hypertrophic Cardiomyopathy (oHCM), sponsored by Cytokinetics.
NCT05186818 is a Phase 3 study of Obstructive Hypertrophic Cardiomyopathy (oHCM) that has completed, run by Cytokinetics. The registered enrollment target is 282 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (63% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05186818, a Phase 3 study of Obstructive Hypertrophic Cardiomyopathy (oHCM), has completed, sponsored by Cytokinetics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 282 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of aficamten (CK-3773274) versus placebo in adults with symptomatic hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract obstruction.
Primary Outcome
The effect of CK-3773274 on exercise capacity in participants with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) was determined through changes in peak oxygen uptake (pVO2) after 24 weeks of treatment. pVO2 was measured by cardiopulmonary exercise testing (CPET) on a treadmill or bicycle. A higher pVO2 indicates better cardiorespiratory fitness.
Conditions Studied
Interventions
- DRUG Aficamten (5 mg, 10 mg, 15 mg, and 20 mg)
- DRUG Placebo to match aficamten
Study Locations (20)
California
- UC San Diego Health - Sulpizio Cardiovascular Center - La Jolla
- Cedars-Sinai Medical Center - Smidt Heart Institute Clinic - Los Angeles
- University of California San Francisco - San Francisco
- Stanford University Hospital - Stanford
Massachusetts
- Massachusetts General Hospital - Boston
- Brigham and Women's Hospital - Boston
- Lahey Hospital & Medical Center - Burlington
Connecticut
- Yale School of Medicine - New Haven
- Yale University School of Medicine - New Haven
Florida
- Holy Cross Hospital / Cardiology Associates - Fort Lauderdale
- Mayo Clinic Florida - Jacksonville
Georgia
- Emory Clinic - Atlanta
- Piedmont Fayette Hospital - Fayetteville
Maryland
- MedStar Medical Group Cardiology at Union Memorial - Baltimore
- Medstar Franklin Square Medical Center - Baltimore
Alaska
- Alaska Heart and Vascular Institute - Anchorage
District of Columbia
- MedStar Washington Hospital Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 282 participants |
| Start Date | 2022-02-01 |
| Est. Completion | 2023-12-18 |
| Phase | Phase 3 |
What the finished NCT05186818 record still lists
NCT05186818 is an interventional study that assigns participants to a tested intervention. The registered 282 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (63% lower).
The record links to 1 condition, with Obstructive Hypertrophic Cardiomyopathy (oHCM) appearing as the primary indexed condition, and to 2 interventions - of which Aficamten (5 mg, 10 mg, 15 mg, and 20 mg) is the first listed.
NCT05186818 names 20 study sites across 11 states, led by California, Massachusetts, Connecticut.
Frequently Asked Questions
What is clinical trial NCT05186818 about?
NCT05186818 is a clinical study titled "Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM". The purpose of this study is to evaluate the efficacy and safety of aficamten (CK-3773274) versus placebo in adults with symptomatic hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract obstruction.
What is the current status of trial NCT05186818?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 282 participants. The study started on 2022-02-01. Estimated completion is 2023-12-18.
What conditions does trial NCT05186818 study?
This clinical trial studies the following conditions: Obstructive Hypertrophic Cardiomyopathy (oHCM).
What interventions are being tested in trial NCT05186818?
The interventions under investigation include: Aficamten (5 mg, 10 mg, 15 mg, and 20 mg) (DRUG), Placebo to match aficamten (DRUG).
Who is sponsoring clinical trial NCT05186818?
This trial is sponsored by Cytokinetics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05186818 being conducted?
This trial has 20 study locations across Alaska, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obstructive Hypertrophic Cardiomyopathy (oHCM)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05186818's enrollment target sits among peer trials
282 1194th of 2000 higher than 807 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02860364 · 282 participants · NA
Comparing Hypothermic Temperatures During Hemiarch Surgery
- NCT04867395 · 282 participants · NA
A Multi-Phase Study Examining Hospital to Home Transitions for Children With Medical Complexity
- NCT05101070 · 282 participants · Phase 1
S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors
- NCT06276491 · 282 participants · Phase 1
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI